Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Marginal Zone Lymphoma Pipeline Insight' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
In February 2025:- BeiGene:- The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
In February 2025:- Regeneron Pharmaceuticals:- This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
In February 2025:- Oncternal Therapeutics Inc.:- This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
In February 2025:- Genmab:- The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese patients with relapsed, progressive or refractory B-cell lymphoma and Japanese patients with B-cell lymphomas that have achieved partial response (PR) or complete response (CR).
In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies
Marginal Zone Lymphoma Emerging Drugs
Tafasitamab: Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
Amdizalisib (HMPL-689): HUTCHMED
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma.
Orelabrutinib: InnoCare Pharma
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
EO2463: Enterome
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
The Marginal Zone Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs
Marginal Zone Lymphoma Companies
Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Marginal Zone Lymphoma Pipeline Report
Coverage- Global
Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight's exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Marginal Zone Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Marginal Zone Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tafasitamab: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Orelabrutinib: InnoCare Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
EO2463: Enterome
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Marginal Zone Lymphoma Key Companies
Marginal Zone Lymphoma Key Products
Marginal Zone Lymphoma- Unmet Needs
Marginal Zone Lymphoma- Market Drivers and Barriers
Marginal Zone Lymphoma- Future Perspectives and Conclusion
Marginal Zone Lymphoma Analyst Views
Marginal Zone Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
6 hours ago
- Toronto Star
Rise of the middle powers. Here's how Canada can wean itself off of U.S. dependence
As leaders of the G7 countries prepare to meet in Kananaskis next week, middle power nations, such as Canada, need to step up and take on leadership roles in restructuring the global economy, shoring up democratic practices internationally and investing in talent to boost productivity and innovation at home. Statistics Canada recently reported that Canada's trade with America had decreased six per cent, largely attributed to tariffs imposed by U.S. President Donald Trump. Opinion articles are based on the author's interpretations and judgments of facts, data and events. More details
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
Billion-dollar battery plant pauses construction amid electric vehicle and tariff uncertainty
COLUMBIA, S.C. (AP) — A Japanese company has halted construction on a $1.6 billion factory in South Carolina to help make batteries for electric BMWs, citing 'policy and market uncertainty.' While AESC didn't specify what those problems are, South Carolina's Republican governor said the company is dealing with the potential loss of federal tax breaks for electric vehicle buyers and incentives for EV businesses as well as tariff uncertainties from President Donald Trump's administration. 'What we're doing is urging caution — let things play out because all of the these changes are taking place,' Gov. Henry McMaster said. AESC announced the suspension in construction of its plant in Florence on Thursday, 'Due to policy and market uncertainty, we are pausing construction at our South Carolina facility at this time,' the company's statement said. AESC promised to restart construction, although it didn't say when, and vowed to meet its commitment to hire 1,600 workers and invest $1.6 billion. The company said it has already invested $1 billion in the Florence plant. The battery maker based in Japan also has facilities in China, the United Kingdom, France, Spain and Germany. In the U.S., AESC has a plant in Tennessee and is building one in Kentucky. The statement didn't mention any changes with other plants. The South Carolina plant is supposed to sell battery cells to BMW, which is building its own battery assembly site near its giant auto plant in Greer. BMW said the construction pause by AESC doesn't change its plans to open its plant in 2026. AESC has already rolled back its South Carolina plans. They announced a second factory on the Florence site, but then said earlier this year that their first plant should be able to handle BMW's demand. That prompted South Carolina officials to withdraw $111 million in help they planned to provide. The company is still getting $135 million in grants from the South Carolina Department of Commerce and $121 million in bonds and the agency said a construction pause won't prompt them to claw back that offer. South Carolina is investing heavily in electric vehicles. Volkswagen-owned Scout Motors plans to invest more than $4 billion and hire 10,000 people for a plant to build its new electric SUVs scheduled to open in 2027. The state has for decades made big bets on foreign manufacturers like BMW, Michelin and Samsung that have paid off with an economic boom this century, but there is uneasiness that Trump's flirtation with high tariffs might stagger or even ruin those important partnerships. McMaster told people to relax as state and business leaders are talking to Trump's administration and things will work out. 'I think the goal of the president and the administration is to have robust economic growth and prosperity and there is no doubt there has to be changes made in our international trade posture and President Trump is addressing that,' McMaster told reporters Thursday.
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
Japanese court rejects damage claims against utility executives over Fukushima disaster
TOKYO (AP) — A Japanese court ruled former executives at the utility managing the tsunami-wrecked Fukushima Daiichi nuclear power plant were not accountable for the 2011 meltdown crisis and do not need to pay damages to the company. The Tokyo High Court ruling on Friday reversed a lower court decision in 2022 ordering four former executives of the Tokyo Electric Power Company Holdings to pay 13 trillion yen ($90 billion) to the company, saying they had failed to take the utmost safety precautions despite knowing the risks of a serious accident in a major tsunami. A magitude 9.0 earthquake and tsunami in March 2011 destroyed key cooling systems at the Fukushima Daiichi plant, causing its three reactors to melt down, spreading large amounts of radiation in the area and keeping tens of thousands of residents from returning home due to radioactive contamination and other safety concerns. The Tokyo District Court ruling three years ago was the only ruling that held the former TEPCO liable for the Fukushima disaster. It upheld the plaintiffs' argument that the executives had neglected to heed experts' long-term tsunami predictions and failed to take adequate tsunami precaution measures soon enough. The court said, however, the long-term tsunani prediction was not considered pressing data requiring immediate tsunami measures and it was understandable the executives had no sense of urgency from the data they had at that time, Kyodo News reported. Friday's ruling is a major disappointment for Fukushima residents and anti-nuclear activists seeking the managements' responsibility in nuclear safety. Plaintiffs and their lawyers criticized the ruling as 'unjust' and said they planned to appeal to the Supreme Court. Hiroyuki Kawai, a plaintiffs' lawyer, criticized the ruling as 'logically flawed,' saying it means nobody can be held liable for any safety negligence because tsunami and earthquake predictions are still impossible today. Monday Mornings The latest local business news and a lookahead to the coming week. A group of more than 40 TEPCO shareholders filed the lawsuit in 2012 demanding five former executives pay the company 22 trillion yen ($153 billion) in damages. The amount of the 2022 ruling against four of the executives was the highest ever ordered in a lawsuit. Japan's top court in March found two former TEPCO executives not guilty of negligence over the Fukushima meltdowns, saying a tsunami of the magnitude that hit the plant was unforeseeable. It was the only criminal trial related to the nuclear accident and the only criminal case related to the nuclear accident.
